Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1166050

Cover Image

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1166050

Peptide Therapeutics Market (Application: Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

PUBLISHED:
PAGES: 211 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5795
PDF (Multi-user License)
USD 8795
PDF (Corporate License)
USD 11795

Add to Cart

Scope of the Report

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global peptide therapeutics market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market peptide therapeutics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

  • WorldWideScience.org
  • Elsevier, Inc.
  • National Institutes of Health (NIH)
  • PubMed
  • NCBI
  • Department of Health Care Service
  • Trade Data Sources
  • Trade Map
  • UN Comtrade
  • Trade Atlas
  • Company Information
  • OneSource Business Browser
  • Hoover's
  • Factiva
  • Bloomberg
  • Mergers & Acquisitions
  • Thomson Mergers & Acquisitions
  • MergerStat
  • Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team's expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd.
  • IBA Worldwide
  • Mevion Medical Systems, Inc.

Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

  • Demographic Data: Healthcare expenditure, inflation rates, and others
  • Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
  • Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
Product Code: TMRGL418

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. White Space Analysis
  • 5.2. Porter's Analysis
  • 5.3. Pipeline Analysis (Phase III)
  • 5.4. Peptide Drug Chemical Structure Trend Analysis
  • 5.5. Separation Media for Peptide Drug Manufacturing
  • 5.6. Covid-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecast, by Application

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Application, 2017-2031
    • 6.3.1. Cancer
    • 6.3.2. Metabolic
    • 6.3.3. CVD
    • 6.3.4. Respiratory
    • 6.3.5. GIT
    • 6.3.6. Anti-infective
    • 6.3.7. Dermatology
    • 6.3.8. CNS
    • 6.3.9. Renal
  • 6.4. Market Attractiveness Analysis, by Application

7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Parenteral
    • 7.3.2. Oral
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast, by Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Type, 2017-2031
    • 8.3.1. Innovative
    • 8.3.2. Generic
  • 8.4. Market Attractiveness Analysis, by Type

9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Technology, 2017-2031
    • 9.3.1. Liquid Phase
    • 9.3.2. Solid Phase
    • 9.3.3. Hybrid Phase
  • 9.4. Market Attractiveness Analysis, by Technology

10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by Type of Molecule, 2017-2031
    • 10.3.1. Vasopressin
    • 10.3.2. Somatostatin
    • 10.3.3. Calcitonin
    • 10.3.4. Natriuretic
  • 10.4. Market Attractiveness Analysis, by Type of Molecule

11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast, by API Peptide Type ,2017-2031
    • 11.3.1. In-house
    • 11.3.2. CMO
  • 11.4. Market Attractiveness Analysis, by API Peptide Type

12. Global Peptide Therapeutics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness Analysis, by Region

13. North America Peptide Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Application,2017-2031
    • 13.2.1. Cancer
    • 13.2.2. Metabolic
    • 13.2.3. CVD
    • 13.2.4. Respiratory
    • 13.2.5. GIT
    • 13.2.6. Anti-infective
    • 13.2.7. Dermatology
    • 13.2.8. CNS
    • 13.2.9. Renal
  • 13.3. Market Value Forecast, by End-user,2017-2031
    • 13.3.1. Parenteral
    • 13.3.2. Oral
  • 13.4. Market Value Forecast, by Type, 2017-2031
    • 13.4.1. Innovative
    • 13.4.2. Generic
  • 13.5. Market Value Forecast, by Technology, 2017-2031
    • 13.5.1. Liquid Phase
    • 13.5.2. Solid Phase
    • 13.5.3. Hybrid Phase
  • 13.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 13.6.1. Vasopressin
    • 13.6.2. Somatostatin
    • 13.6.3. Calcitonin
    • 13.6.4. Natriuretic
  • 13.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 13.7.1. In-house
    • 13.7.2. CMO
  • 13.8. Market Value Forecast, by Country, 2017-2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Application
    • 13.9.2. By Route of Administration
    • 13.9.3. By Type
    • 13.9.4. By Technology
    • 13.9.5. By Type of Molecule
    • 13.9.6. By API Peptide Type
    • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Application, 2017-2031
    • 14.2.1. Cancer
    • 14.2.2. Metabolic
    • 14.2.3. CVD
    • 14.2.4. Respiratory
    • 14.2.5. GIT
    • 14.2.6. Anti-infective
    • 14.2.7. Dermatology
    • 14.2.8. CNS
    • 14.2.9. Renal
  • 14.3. Market Value Forecast, by End-user, 2017-2031
    • 14.3.1. Parenteral
    • 14.3.2. Oral
  • 14.4. Market Value Forecast, by Type, 2017-2031
    • 14.4.1. Innovative
    • 14.4.2. Generic
  • 14.5. Market Value Forecast, by Technology, 2017-2031
    • 14.5.1. Liquid Phase
    • 14.5.2. Solid Phase
    • 14.5.3. Hybrid Phase
  • 14.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 14.6.1. Vasopressin
    • 14.6.2. Somatostatin
    • 14.6.3. Calcitonin
    • 14.6.4. Natriuretic
  • 14.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 14.7.1. In-house
    • 14.7.2. CMO
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Spain
    • 14.8.5. Italy
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Application
    • 14.9.2. By Route of Administration
    • 14.9.3. By Type
    • 14.9.4. By Technology
    • 14.9.5. By Type of Molecule
    • 14.9.6. By API Peptide Type
    • 14.9.7. By Country/Sub-region

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Application, 2017-2031
    • 15.2.1. Cancer
    • 15.2.2. Metabolic
    • 15.2.3. CVD
    • 15.2.4. Respiratory
    • 15.2.5. GIT
    • 15.2.6. Anti-infective
    • 15.2.7. Dermatology
    • 15.2.8. CNS
    • 15.2.9. Renal
  • 15.3. Market Value Forecast, by End-user, 2017-2031
    • 15.3.1. Parenteral
    • 15.3.2. Oral
  • 15.4. Market Value Forecast, by Type, 2017-2031
    • 15.4.1. Innovative
    • 15.4.2. Generic
  • 15.5. Market Value Forecast, by Technology, 2017-2031
    • 15.5.1. Liquid Phase
    • 15.5.2. Solid Phase
    • 15.5.3. Hybrid Phase
  • 15.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 15.6.1. Vasopressin
    • 15.6.2. Somatostatin
    • 15.6.3. Calcitonin
    • 15.6.4. Natriuretic
  • 15.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 15.7.1. In-house
    • 15.7.2. CMO
  • 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Application
    • 15.9.2. By Route of Administration
    • 15.9.3. By Type
    • 15.9.4. By Technology
    • 15.9.5. By Type of Molecule
    • 15.9.6. By API Peptide Type
    • 15.9.7. By Country/Sub-region

16. Latin America Peptide Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Application, 2017-2031
    • 16.2.1. Cancer
    • 16.2.2. Metabolic
    • 16.2.3. CVD
    • 16.2.4. Respiratory
    • 16.2.5. GIT
    • 16.2.6. Anti-infective
    • 16.2.7. Dermatology
    • 16.2.8. CNS
    • 16.2.9. Renal
  • 16.3. Market Value Forecast, by End-user, 2017-2031
    • 16.3.1. Parenteral
    • 16.3.2. Oral
  • 16.4. Market Value Forecast, by Type, 2017-2031
    • 16.4.1. Innovative
    • 16.4.2. Generic
  • 16.5. Market Value Forecast, by Technology,2017-2031
    • 16.5.1. Liquid Phase
    • 16.5.2. Solid Phase
    • 16.5.3. Hybrid Phase
  • 16.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 16.6.1. Vasopressin
    • 16.6.2. Somatostatin
    • 16.6.3. Calcitonin
    • 16.6.4. Natriuretic
  • 16.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 16.7.1. In-house
    • 16.7.2. CMO
  • 16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Application
    • 16.9.2. By Route of Administration
    • 16.9.3. By Type
    • 16.9.4. By Technology
    • 16.9.5. By Type of Molecule
    • 16.9.6. By API Peptide Type
    • 16.9.7. By Country/Sub-region

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Application, 2017-2031
    • 17.2.1. Cancer
    • 17.2.2. Metabolic
    • 17.2.3. CVD
    • 17.2.4. Respiratory
    • 17.2.5. GIT
    • 17.2.6. Anti-infective
    • 17.2.7. Dermatology
    • 17.2.8. CNS
    • 17.2.9. Renal
  • 17.3. Market Value Forecast, by End-user, 2017-2031
    • 17.3.1. Parenteral
    • 17.3.2. Oral
  • 17.4. Market Value Forecast, by Type, 2017-2031
    • 17.4.1. Innovative
    • 17.4.2. Generic
  • 17.5. Market Value Forecast, by Technology, 2017-2031
    • 17.5.1. Liquid Phase
    • 17.5.2. Solid Phase
    • 17.5.3. Hybrid Phase
  • 17.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 17.6.1. Vasopressin
    • 17.6.2. Somatostatin
    • 17.6.3. Calcitonin
    • 17.6.4. Natriuretic
  • 17.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 17.7.1. In-house
    • 17.7.2. CMO
  • 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Application
    • 17.9.2. By Route of Administration
    • 17.9.3. By Type
    • 17.9.4. By Technology
    • 17.9.5. By Type of Molecule
    • 17.9.6. By API Peptide Type
    • 17.9.7. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (by tier and size of companies)
  • 18.2. Market Share Analysis, by Company, 2021
  • 18.3. Company Profiles
    • 18.3.1. Amgen, Inc.
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. SWOT Analysis
      • 18.3.1.4. Strategic Overview
    • 18.3.2. Bachem Holding AG
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. SWOT Analysis
      • 18.3.2.4. Strategic Overview
    • 18.3.3. Eli Lilly and Company
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. SWOT Analysis
      • 18.3.3.4. Strategic Overview
    • 18.3.4. F. Hoffmann-La Roche Ltd.
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. SWOT Analysis
      • 18.3.4.4. Strategic Overview
    • 18.3.5. GlaxoSmithKline plc
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. SWOT Analysis
      • 18.3.5.4. Strategic Overview
    • 18.3.6. Novartis AG
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. SWOT Analysis
      • 18.3.6.4. Strategic Overview
    • 18.3.7. Pfizer, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. SWOT Analysis
      • 18.3.7.4. Strategic Overview
    • 18.3.8. Sanofi
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. SWOT Analysis
      • 18.3.8.4. Strategic Overview
    • 18.3.9. Takeda Pharmaceutical Company Limited
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. SWOT Analysis
      • 18.3.9.4. Strategic Overview
    • 18.3.10. Teva Pharmaceutical Industries Ltd.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. SWOT Analysis
      • 18.3.10.4. Strategic Overview
Product Code: TMRGL418

List of Table

  • Table 01: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 02: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2021-2031
  • Table 03: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 04: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 05: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 06: Global API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 07: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021-2031
  • Table 08: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2021-2031
  • Table 09: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021-2031
  • Table 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021-2031
  • Table 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021-2031
  • Table 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021-2031
  • Table 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021-2031
  • Table 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021-2031
  • Table 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021-2031
  • Table 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021-2031
  • Table 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021-2031
  • Table 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021-2031
  • Table 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031
  • Table 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021-2031
  • Table 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021-2031
  • Table 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021-2031

List of Figures

  • Figure 01: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 02: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 03: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 04: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 05: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 06: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 07: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 08: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 09: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 12: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2021-2031
  • Figure 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2021-2031
  • Figure 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2021-2031
  • Figure 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 18: Global Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 19: Global Innovative Peptide Therapeutics Market Size (US$ Mn), 2021-2031
  • Figure 20: Global Generic Peptide Therapeutics Market Size (US$ Mn), 2021-2031
  • Figure 21: Global Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 21: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 22: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 23: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 24: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 25: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 26: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2021 and 2031
  • Figure 27: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 28: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 29: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 30: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 31: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 32: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 33: Global Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule, 2022-2031
  • Figure 34: Global API Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 35: Global In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 36: Global CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2021-2031
  • Figure 37: Global API Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 38: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 39: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 40: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 41: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 42: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 43: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 44: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 45: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 46: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 50: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 51: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 52: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 53: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 54: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 55: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 56: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 60: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 61: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 62: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 63: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 64: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 68: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 69: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 70: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 71: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 75: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 76: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 77: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021-2031
  • Figure 78: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 82: Peptide Therapeutics Market Share Analysis, by Company, 2021
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!